Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma

Laba, Pingcuo; Wang, Jianfeng; Zhang, Jin

doi:10.1186/s12885-018-4747-1

Cited by 11 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…129 Specially, studies also found that IDH1 is significantly downregulated in clear cell renal cell carcinoma (ccRCC) compared with normal kidney cells, suggesting that IDH1 may function as a candidate tumor suppressor for ccRCC. 130,131 Most studies indicate that IDH2 is also significantly upregulated in ESCC, 132 ovarian cancer, 133 lung cancer and other types of cancer, 134 playing a pro-oncogenic role. Overexpression of IDH2 decreases ROS levels and increases cancer cell growth.…”

Section: Pentose Phosphate Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications

Lin

Tian

et al. 2020

Sig Transduct Target Ther

269

196

View full text Add to dashboard Cite

Nicotinamide adenine dinucleotide phosphate (NADPH) is an essential electron donor in all organisms, and provides the reducing power for anabolic reactions and redox balance. NADPH homeostasis is regulated by varied signaling pathways and several metabolic enzymes that undergo adaptive alteration in cancer cells. The metabolic reprogramming of NADPH renders cancer cells both highly dependent on this metabolic network for antioxidant capacity and more susceptible to oxidative stress. Modulating the unique NADPH homeostasis of cancer cells might be an effective strategy to eliminate these cells. In this review, we summarize the current existing literatures on NADPH homeostasis, including its biological functions, regulatory mechanisms and the corresponding therapeutic interventions in human cancers, providing insights into therapeutic implications of targeting NADPH metabolism and the associated mechanism for cancer therapy.

show abstract

Section: Pentose Phosphate Pathwaymentioning

confidence: 99%

Section: Molecular Mechanisms Of Nadph Homeostasis In Cancermentioning

confidence: 99%

NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications

Lin

Tian

et al. 2020

Sig Transduct Target Ther

269

196

View full text Add to dashboard Cite

show abstract

“…Alterations in genes ( SDHB ) encoding yet another TCA cycle enzyme, succinate dehydrogenase, have been reported in patients with hereditary paragangliomatosis with phaeochromocytomas and in some ccRCC cases [6]. Additionally, low expression of isocitrate dehydrogenase (IDH1) was recently reported to be associated with poor prognosis in ccRCC [7]. Isocitrate dehydrogenase catalyzes the conversion of the TCA intermediate isocitrate to α-ketoglutarate (alphaKG).…”

Section: Introductionmentioning

confidence: 99%

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

et al. 2019

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a heterogeneous malignancy which often develops and progresses asymptomatically. Benign oncocytomas are morphologically similar to malignant chromophobe RCC and distinguishing between these two forms on cross-sectional imaging remains a challenge. Therefore, RCC-specific biomarkers are urgently required for accurate and non-invasive, pre-surgical diagnosis of benign lesions. We have previously shown that dysregulation in glycolytic and tricarboxylic acid cycle intermediates can distinguish benign lesions from RCC in a stage-specific manner. In this study, preoperative fasting urine samples from patients with renal masses were assessed by ¹H nuclear magnetic resonance (NMR). Significant alterations in levels of tricarboxylic acid cycle intermediates, carnitines and its derivatives were detected in RCC relative to benign masses and in oncocytomas vs. chromophobe RCC. Orthogonal Partial Least Square Discriminant Analysis plots confirmed stage discrimination between benign vs. pT1 (R2 = 0.42, Q2 = 0.27) and benign vs. pT3 (R2 = 0.48, Q2 = 0.32) and showed separation for oncocytomas vs. chromophobe RCC (R2 = 0.81, Q2 = 0.57) and oncocytomas vs. clear cell RCC (R2 = 0.32, Q2 = 0.20). This study validates our previously described metabolic profile distinguishing benign tumors from RCC and presents a novel metabolic signature for oncocytomas which may be exploited for diagnosis before cross-sectional imaging.

show abstract

“…In these studies, the expression of miR-30c-5p in RCC is downregulated which would suggest an upregulation of IDH's mRNA expression. However, this protein was shown to be downregulated in this tumor model [85]. In fact, a single mRNA can be regulate by several miRNAs, making the miRNA:mRNA expression not always inversely correlated.…”

Section: Krebs Cyclementioning

confidence: 81%

The Impact of Oxidoreductases-Related MicroRNAs in Glucose Metabolism of Renal Cell Carcinoma and Prostate Cancer

Morais¹,

Dias²,

Prior³

et al. 2021

Oxidoreductase

View full text Add to dashboard Cite

The reprogramming of metabolism is one of cancer hallmarks. Glucose’s metabolism, as one of the main fuels of cancer cells, has been the focus of several research studies in the oncology field. However, because cancer is a heterogeneous disease, the disruptions in glucose metabolism are highly variable depending of the cancer. In fact, Renal Cell Carcinoma (RCC) and Prostate Cancer (PCa), the most lethal and common urological neoplasia, respectively, show different disruptions in the main pathways of glucose catabolism: glycolysis, lactate fermentation and Krebs Cycle. Oxidoreductases are a class of enzymes that catalyze electrons transfer from one molecule to another and are present in these three pathways, posing as an opportunity to better understand these catabolic deregulations. Furthermore, nowadays it is recognized that their expression is modulated by microRNAs (miRNAs), in this book chapter, we selected the known miRNAs that directly target these oxidoreductases and analyzed their deregulation in both cancers. The characterization of these miRNAs opens a new door that could be applied in patients’ stratification and therapy monitorization because of their potential as cancer biomarkers. Additionally, their delivery to cancer cells, using glucose capped NPs could help establish new therapeutic strategies that would improve RCC and PCa management.

show abstract

Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma

Cited by 11 publications

References 42 publications

NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications

NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications

Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas

The Impact of Oxidoreductases-Related MicroRNAs in Glucose Metabolism of Renal Cell Carcinoma and Prostate Cancer

Contact Info

Product

Resources

About